Joseph Burkhart, PharmD

Articles by Joseph Burkhart, PharmD

First-Line HIV Therapy: Integrase Inhibitors, Exceptions, and HLA-B*5701 Testing

ByChristina M. Madison, PharmD, FCCP, AAHIVP,Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES,Spencer Durham, PharmD, FCCP, BCPS, BCIDP,Joseph Burkhart, PharmD,Tram Nguyen, Pharm.D.

September 30th 2026

Integrase inhibitors remain the clear first choice, yet prior long-acting PrEP exposure and the practical realities of same-day starts are reshaping when alternatives make more sense.

HIV Treatment Basics: Mechanisms, 2026 Guideline Updates, and Rapid ART Start

ByChristina M. Madison, PharmD, FCCP, AAHIVP,Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES,Spencer Durham, PharmD, FCCP, BCPS, BCIDP,Joseph Burkhart, PharmD,Tram Nguyen, Pharm.D.

September 30th 2026

Before weighing new options, the panel resets the foundation: how antiretroviral classes work, what the 2026 DHHS update actually changed, and why therapy should start as soon as possible.

Joseph Burkhart, PharmD

Articles by Joseph Burkhart, PharmD

First-Line HIV Therapy: Integrase Inhibitors, Exceptions, and HLA-B*5701 Testing

HIV Treatment Basics: Mechanisms, 2026 Guideline Updates, and Rapid ART Start

Latest Updated Articles

Trending on Pharmacy Times

FDA Approves Tiratricol, First Treatment for MCT8 Deficiency

Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says

Sotatercept in ERS PAH Guidelines: What Pharmacists Should Watch

Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID

Pharmacists as the Go-To Source for HIV Prevention Guidance